Different patterns of failure in two treatment regimens for primary central nervous system lymphoma, a retrospective analysis of 124 cases in Taiwan
Authors:
Open Access
- 7 September 2023
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (8) , 5327-5336
Abstract
To explore prognostic factors and outcomes of primary central nervous system lymphoma (PCNSL) of diffuse large B-cell lymphoma (DLBCL) in Taiwan, 124 PCNSL-DLBCL patients (from 1995 to 2021) were retrospectively analyzed. Mainly, two treatment modalities including sandwich chemoradiotherapy and modified MATRix regimen were employed in these patients. Overall survival (OS) was determined by log-rank test and time-dependent Cox analysis. Median OS of all patients was 27.1 months. 47 (37.9%) patients who underwent sandwich chemoradiotherapy had a complete remission (CR) rate of 87.2%, median OS of 53.9 months, and progression free survival (PFS) of 42.9 months. 11 (8.9%) patients who underwent modified MATRix regimen had CR rate of 72.7%, median OS of 18.9, and PFS of 11.2 months. There are no significant OS differences between treatment groups or addition of Rituximab. Patients treated with the modified MATRix regimen experienced a higher early mortality rate followed by a survival plateau. IELSG low-risk group had significantly improved OS and PFS than IELSG intermediate- or high-risk group. In multivariant analysis, age > 60 years old and bilateral cerebral lesions are associated with significantly inferior OS. Sandwich chemoradiotherapy demonstrated better early survival and reduced treatment-related toxicity for PCNSL patients compared to the modified MATRix regimen. However, the long-term follow-up revealed a higher rate of treatment failure events in the sandwich chemoradiotherapy group. IELSG and MSKCC scores served as reliable risk assessment models. Incorporating bilateral cerebral lesions as a risk factor further improved risk evaluation.Keywords
Funding Information
- Chang Gung Memorial Hospital, Linkou (CORPG3F0671, CMRPG3C1701)
This publication has 29 references indexed in Scilit:
- Evaluation of Memorial Sloan‐Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphomaBrain and Behavior, 2018
- Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agentsHematology-American Society Hematology Education Program, 2017
- Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialThe Lancet Haematology, 2017
- Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialThe Lancet Haematology, 2016
- Trends in primary central nervous system lymphoma incidence and survival in the U.S.British Journal of Haematology, 2016
- High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trialThe Lancet, 2009
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic ModelJournal of Clinical Oncology, 2006
- Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group ExperienceJournal of Clinical Oncology, 2003
- Combined modality therapy for primary CNS lymphoma.Journal of Clinical Oncology, 1992